Baicalein alleviates diabetic peripheral neuropathy through inhibition of oxidative-nitrosative stress and p38 MAPK activation

Experimental Neurology

Volumn 230, Issue 1, 2011, Pages 106-113

  Stavniichuk, Roman ^a   Drel, Viktor R ^a   Shevalye, Hanna ^a   Maksimchyk, Yury ^a   Kuchmerovska, Tamara M ^b   Nadler, Jerry L ^c   Obrosova, Irina G ^a  

^a PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^b PALLADIN INSTITUTE OF BIOCHEMISTRY   (Ukraine)

^c EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

12 15 lipoxygenase; Baicalein; Diabetic peripheral neuropathy; Oxidative nitrosative stress; P38 mitogen activated protein kinase; Sorbitol pathway of glucose metabolism

Indexed keywords

12 HYDROXYICOSATETRAENOIC ACID; ARACHIDONATE 12 LIPOXYGENASE; ARACHIDONATE 15 LIPOXYGENASE; BAICALEIN; GLUCOSE; MITOGEN ACTIVATED PROTEIN KINASE P38; SORBITOL; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ARTICLE; CELL DENSITY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEUROPATHY; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; HYPERGLYCEMIA; IMMUNOHISTOCHEMISTRY; MOUSE; NERVE CONDUCTION; NITRATION; NITROSATIVE STRESS; NOCICEPTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCIATIC NERVE; SENSORY NERVE; SPECTROFLUOROMETRY; STREPTOZOCIN DIABETES; TACTILE STIMULATION; TREATMENT OUTCOME; WESTERN BLOTTING;

ANIMALS; ANTIOXIDANTS; ARACHIDONATE 12-LIPOXYGENASE; ARACHIDONATE 15-LIPOXYGENASE; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEUROPATHIES; DISEASE MODELS, ANIMAL; FLAVANONES; GENE EXPRESSION REGULATION; HYPERALGESIA; MICE; MICE, INBRED C57BL; NEURAL CONDUCTION; OLIGONUCLEOTIDES, ANTISENSE; OXIDATIVE STRESS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; REACTION TIME; RECEPTORS, EICOSANOID; SCIATIC NERVE; SPINAL CORD; STATISTICS, NONPARAMETRIC; TYROSINE;

EID: 79958027982     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2011.04.002     Document Type: Article

References (84)

1. Androutsopoulos V.P., Ruparelia K., Arroo R.R., Tsatsakis A.M., Spandidos D.A. CYP1-mediated antiproliferative activity of dietary flavonoids in MDA-MB-468 breast cancer cells. Toxicology 2010, 264:162-170.
2. Bierhaus A., Haslbeck K.M., Humpert P.M., Liliensiek B., Dehmer T., Morcos M., Sayed A.A., Andrassy M., Schiekofer S., Schneider J.G., Schulz J.B., Heuss D., Neundörfer B., Dierl S., Huber J., Tritschler H., Schmidt A.M., Schwaninger M., Haering H.U., Schleicher E., Kasper M., Stern D.M., Arnold B., Nawroth P.P. Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin superfamily. J. Clin. Invest. 2004, 114:1741-1751.
3. Bril V., Hirose T., Tomioka S., Buchanan R. Ranirestat for the management of diabetic sensorimotor polyneuropathy. Diabetes Care 2009, 32:1256-1260. Ranirestat Study Group.
4. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414:813-820.
5. Brussee V., Guo G., Dong Y., Cheng C., Martinez J.A., Smith D., Glazner G.W., Fernyhough P., Zochodne D.W. Distal degenerative sensory neuropathy in a long-term type 2 diabetes rat model. Diabetes 2008, 57:1664-1673.
6. Cameron N.E., Cotter M.A. Pro-inflammatory mechanisms in diabetic neuropathy: focus on the nuclear factor kappa B pathway. Curr. Drug Targets 2008, 9:60-67.
7. Cameron N.E., Cotter M.A., Jack A.M., Basso M.D., Hohman T.C. Protein kinase C effects on nerve function, perfusion, Na(+), K(+)-ATPase activity and glutathione content in diabetic rats. Diabetologia 1999, 42:1120-1130.
8. Cameron N.E., Tuck Z., McCabe L., Cotter M.A. Effect of the hydroxyl radical scavenger, dimethylthiourea, on peripheral nerve tissue perfusion, conduction velocity and nociception in experimental diabetes. Diabetologia 2001, 44:1161-1169.
9. Cameron N.E., Gibson T.M., Nangle M.R., Cotter M.A. Inhibitors of advanced glycation end product formation and neurovascular dysfunction in experimental diabetes. Ann. N.Y. Acad. Sci. 2005, 1043:784-792.
10. Chattopadhyay M., Krisky D., Wolfe D., Glorioso J.C., Mata M., Fink D.J. HSV-mediated gene transfer of vascular endothelial growth factor to dorsal root ganglia prevents diabetic neuropathy. Gene Ther. 2005, 12:1377-1384.
11. Chen M., Yang Z.D., Smith K.M., Carter J.D., Nadler J.L. Activation of 12-lipoxygenase in proinflammatory cytokine-mediated beta cell toxicity. Diabetologia 2005, 48:486-495.
12. Christianson J.A., Ryals J.M., Johnson M.S., Dobrowsky R.T., Wright D.E. Neurotrophic modulation of myelinated cutaneous innervation and mechanical sensory loss in diabetic mice. Neuroscience 2007, 145:303-313.
13. Conrad D.J., Lu M. Regulation of human 12/15-lipoxygenase by Stat6-dependent transcription. Am. J. Respir. Cell Mol. Biol. 2000, 22:226-234.
14. Coppey L.J., Gellett J.S., Davidson E.P., Dunlap J.A., Lund D.D., Salvemini D., Yorek M.A. Effect of M40403 treatment of diabetic rats on endoneurial blood flow, motor nerve conduction velocity and vascular function of epineurial arterioles of the sciatic nerve. Br. J. Pharmacol. 2001, 134:21-29.
15. Coppey L.J., Gellett J.S., Davidson E.P., Dunlap J.A., Lund D.D., Yorek M.A. Effect of antioxidant treatment of streptozotocin-induced diabetic rats on endoneurial blood flow, motor nerve conduction velocity, and vascular reactivity of epineurial arterioles of the sciatic nerve. Diabetes 2001, 50:1927-1937.
16. Cotter L., Davidson E., Lu B., Gerard C., Yorek M. Vasopeptidase inhibitor ilepatril (AVE7688) prevents obesity- and diabetes-induced neuropathy in C57Bl/6J mice. Neuropharmacology 2011, 60:259-266.
17. Cotter M.A., Mirrlees D.J., Cameron N.E. Neurovascular interactions between aldose reductase and angiotensin-converting enzyme inhibition in diabetic rats. Eur. J. Pharmacol. 2001, 417:223-230.
18. Cui L., Zhang X., Yang R., Liu L., Wang L., Li M., Du W. Baicalein is neuroprotective in rat MCAO model: role of 12/15-lipoxygenase, mitogen-activated protein kinase and cytosolic phospholipase A2. Pharmacol. Biochem. Behav. 2010, 96:469-475.
19. Doupis J., Lyons T.E., Wu S., Gnardellis C., Dinh T., Veves A. Microvascular reactivity and inflammatory cytokines in painful and painless peripheral diabetic neuropathy. J. Clin. Endocrinol. Metab. 2009, 94:2157-2163.
20. Drel V.R., Mashtalir N., Ilnytska O., Shin J., Li F., Lyzogubov V.V., Obrosova I.G. The leptin-deficient (ob/ob) mouse: a new animal model of peripheral neuropathy of type 2 diabetes and obesity. Diabetes 2006, 55:3335-3343.
21. Drel V.R., Pacher P., Stevens M.J., Obrosova I.G. Aldose reductase inhibition counteracts nitrosative stress and poly(ADP-ribose) polymerase activation in diabetic rat kidney and high-glucose-exposed human mesangial cells. Free Radic. Biol. Med. 2006, 40:1454-1465.
22. Drel V.R., Pacher P., Vareniuk I., Pavlov I.A., Ilnytska O., Lyzogubov V.V., Bell S.R., Groves J.T., Obrosova I.G. Evaluation of the peroxynitrite decomposition catalyst Fe(III) tetra-mesitylporphyrin octasulfonate on peripheral neuropathy in a mouse model of type 1 diabetes. Int. J. Mol. Med. 2007, 20:783-792.
23. Drel V.R., Pacher P., Vareniuk I., Pavlov I., Ilnytska O., Lyzogubov V.V., Tibrewala J., Groves J.T., Obrosova I.G. A peroxynitrite decomposition catalyst counteracts sensory neuropathy in streptozotocin-diabetic mice. Eur. J. Pharmacol. 2007, 569:48-58.
24. Drel V.R., Lupachyk S., Shevalye H., Vareniuk I., Xu W., Zhang J., Delamere N.A., Shahidullah M., Slusher B., Obrosova I.G. New therapeutic and biomarker discovery for peripheral diabetic neuropathy: PARP inhibitor, nitrotyrosine, and tumor necrosis factor-{alpha}. Endocrinology 2010, 151:2547-2555.
25. Du Y., Tang J., Li G., Berti-Mattera L., Lee C.A., Bartkowski D., Gale D., Monahan J., Niesman M.R., Alton G., Kern T.S. Effects of p38 MAPK inhibition on early stages of diabetic retinopathy and sensory nerve function. Invest. Ophthalmol. Vis. Sci. 2010, 51:2158-2164.
26. El-Remessy A.B., Abou-Mohamed G., Caldwell R.W., Caldwell R.B. High glucose-induced tyrosine nitration in endothelial cells: role of eNOS uncoupling and aldose reductase activation. Invest. Ophthalmol. Vis. Sci. 2003, 44:3135-3143.
27. Francis G., Martinez J., Liu W., Nguyen T., Ayer A., Fine J., Zochodne D., Hanson L.R., Frey W.H., Toth C. Intranasal insulin ameliorates experimental diabetic neuropathy. Diabetes 2009, 58:934-945.
28. Gerhardinger C., Dagher Z., Sebastiani P., Park Y.S., Lorenzi M. The transforming growth factor-beta pathway is a common target of drugs that prevent experimental diabetic retinopathy. Diabetes 2009, 58:1659-1667.
29. Gohil K., Packer L. Bioflavonoid-rich botanical extracts show antioxidant and gene regulatory activity. Ann. N.Y. Acad. Sci. 2002, 957:70-77.
30. Goss J.R., Goins W.F., Lacomis D., Mata M., Glorioso J.C., Fink D.J. Herpes simplex-mediated gene transfer of nerve growth factor protects against peripheral neuropathy in streptozotocin-induced diabetes in the mouse. Diabetes 2002, 51:2227-2232.
31. Greene D.A., Arezzo J.C., Brown M.B. Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy. Zenarestat Study Group. Neurology 1999, 53:580-591.
32. Ho E.C., Lam K.S., Chen Y.S., Yip J.C., Arvindakshan M., Yamagishi S., Yagihashi S., Oates P.J., Ellery C.A., Chung S.S., Chung S.K. Aldose reductase-deficient mice are protected from delayed motor nerve conduction velocity, increased c-Jun NH2-terminal kinase activation, depletion of reduced glutathione, increased superoxide accumulation, and DNA damage. Diabetes 2006, 55:1946-1953.
33. Hong D.P., Fink A.L., Uversky V.N. Structural characteristics of alpha-synuclein oligomers stabilized by the flavonoid baicalein. J. Mol. Biol. 2008, 383:214-223.
34. Hotta N., Toyota T., Matsuoka K., Shigeta Y., Kikkawa R., Kaneko T., Takahashi A., Sugimura K., Koike Y., Ishii J., Sakamoto N. Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group study. Diabetes Care 2001, 24:1776-1782. SNK-860 Diabetic Neuropathy Study Group.
35. Huang Y., Tsang S.Y., Yao X., Chen Z.Y. Biological properties of baicalein in cardiovascular system. Curr. Drug Targets Cardiovasc. Haematol. Disord. 2005, 5:177-184.
36. Kang S.W., Natarajan R., Shahed A., Nast C.C., LaPage J., Mundel P., Kashtan C., Adler S.G. Role of 12-lipoxygenase in the stimulation of p38 mitogen-activated protein kinase and collagen alpha5(IV) in experimental diabetic nephropathy and in glucose-stimulated podocytes. J. Am. Soc. Nephrol. 2003, 14:3178-3187.
37. Kellogg A.P., Wiggin T.D., Larkin D.D., Hayes J.M., Stevens M.J., Pop-Busui R. Protective effects of cyclooxygenase-2 gene inactivation against peripheral nerve dysfunction and intraepidermal nerve fiber loss in experimental diabetes. Diabetes 2007, 56:2997-3005.
38. Kumar A., Sharma S.S. NF-kappaB inhibitory action of resveratrol: a probable mechanism of neuroprotection in experimental diabetic neuropathy. Biochem. Biophys. Res. Commun. 2010, 394:360-365.
39. Li F., Drel V.R., Szabó C., Stevens M.J., Obrosova I.G. Low-dose poly(ADP-ribose) polymerase inhibitor-containing combination therapies reverse early peripheral diabetic neuropathy. Diabetes 2005, 54:1514-1522.
40. McGuire J.F., Rouen S., Siegfreid E., Wright D.E., Dobrowsky R.T. Caveolin-1 and altered neuregulin signaling contribute to the pathophysiological progression of diabetic peripheral neuropathy. Diabetes 2009, 58:2677-2686.
41. Nagamatsu M., Nickander K.K., Schmelzer J.D., Raya A., Wittrock D.A., Tritschler H., Low P.A. Lipoic acid improves nerve blood flow, reduces oxidative stress, and improves distal nerve conduction in experimental diabetic neuropathy. Diabetes Care 1995, 18:1160-1167.
42. Nakae M., Kamiya H., Naruse K., Horio N., Ito Y., Mizubayashi R., Hamada Y., Nakashima E., Akiyama N., Kobayashi Y., Watarai A., Kimura N., Horiguchi M., Tabata Y., Oiso Y., Nakamura J. Effects of basic fibroblast growth factor on experimental diabetic neuropathy in rats. Diabetes 2006, 55:1470-1477.
43. Nakamura J., Kato K., Hamada Y., Nakayama M., Chaya S., Nakashima E., Naruse K., Kasuya Y., Mizubayashi R., Miwa K., Yasuda Y., Kamiya H., Ienaga K., Sakakibara F., Koh N., Hotta N. A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. Diabetes 1999, 48:2090-2095.
44. Natarajan R., Bai W., Rangarajan V., Gonzales N., Gu J.L., Lanting L., Nadler J.L. Platelet-derived growth factor BB mediated regulation of 12-lipoxygenase in porcine aortic smooth muscle cells. J. Cell. Physiol. 1996, 169:391-400.
45. Obrosova I.G. Diabetes and the peripheral nerve. Biochim. Biophys. Acta 2009, 1792:931-940.
46. Obrosova I.G., Fathallah L., Lang H.J., Greene D.A. Evaluation of a sorbitol dehydrogenase inhibitor on diabetic peripheral nerve metabolism: a prevention study. Diabetologia 1999, 42:1187-1194.
47. Obrosova I.G., Van Huysen C., Fathallah L., Cao X.C., Greene D.A., Stevens M.J. An aldose reductase inhibitor reverses early diabetes-induced changes in peripheral nerve function, metabolism, and antioxidative defense. FASEB J. 2002, 2002(16):123-125.
48. Obrosova I.G., Minchenko A.G., Vasupuram R., White L., Abatan O.I., Kumagai A.K., Frank R.N., Stevens M.J. Aldose reductase inhibitor fidarestat prevents retinal oxidative stress and vascular endothelial growth factor overexpression in streptozotocin-diabetic rats. Diabetes 2003, 52:864-871.
49. Obrosova I.G., Li F., Abatan O.I., Forsell M.A., Komjáti K., Pacher P., Szabó C., Stevens M.J. Role of poly(ADP-ribose) polymerase activation in diabetic neuropathy. Diabetes 2004, 53:711-720.
50. Obrosova I.G., Mabley J.G., Zsengellér Z., Charniauskaya T., Abatan O.I., Groves J.T., Szabó C. Role for nitrosative stress in diabetic neuropathy: evidence from studies with a peroxynitrite decomposition catalyst. FASEB J. 2005, 19:401-403.
51. Obrosova I.G., Drel V.R., Oltman C.L., Mashtalir N., Tibrewala J., Groves J.T., Yorek M.A. Role of nitrosative stress in early neuropathy and vascular dysfunction in streptozotocin-diabetic rats. Am. J. Physiol. Endocrinol. Metab. 2007, 293:E1645-E1655.
52. Obrosova I.G., Ilnytska O., Lyzogubov V.V., Pavlov I.A., Mashtalir N., Nadler J.L., Drel V.R. High-fat diet induced neuropathy of pre-diabetes and obesity: effects of "healthy" diet and aldose reductase inhibition. Diabetes 2007, 56:2598-2608.
53. Obrosova I.G., Xu W., Lyzogubov V.V., Ilnytska O., Mashtalir N., Vareniuk I., Pavlov I.A., Zhang J., Slusher B., Drel V.R. PARP inhibition or gene deficiency counteracts intraepidermal nerve fiber loss and neuropathic pain in advanced diabetic neuropathy. Free Radic. Biol. Med. 2008, 44:972-981.
54. Obrosova I.G., Stavniichuk R., Drel V.R., Shevalye H., Vareniuk I., Nadler J.L., Schmidt R.E. Different roles of 12/15-lipoxygenase in diabetic large and small fiber peripheral and autonomic neuropathies. Am. J. Pathol. 2010, 177:1436-1447.
55. Pallast S., Arai K., Pekcec A., Yigitkanli K., Yu Z., Wang X., Lo E.H., van Leyen K. Increased nuclear apoptosis-inducing factor after transient focal ischemia: a 12/15-lipoxygenase-dependent organelle damage pathway. J. Cereb. Blood Flow Metab. 2010, 30:1157-1167.
56. Price S.A., Gardiner N.J., Duran-Jimenez B., Zeef L.A., Obrosova I.G., Tomlinson D.R. Thioredoxin interacting protein is increased in sensory neurons in experimental diabetes. Brain Res. 2006, 1116:206-214.
57. Purves T., Middlemas A., Agthong S., Jude E.B., Boulton A.J., Fernyhough P., Tomlinson D.R. A role for mitogen-activated protein kinases in the etiology of diabetic neuropathy. FASEB J. 2001, 15:2508-2514.
58. Quattrini C., Tavakoli M., Jeziorska M., Kallinikos P., Tesfaye S., Finnigan J., Marshall A., Boulton A.J., Efron N., Malik R.A. Surrogate markers of small fiber damage in human diabetic neuropathy. Diabetes 2007, 56:2148-2154.
59. Reddy M.A., Thimmalapura P.R., Lanting L., Nadler J.L., Fatima S., Natarajan R. The oxidized lipid and lipoxygenase product 12(S)-hydroxyeicosatetraenoic acid induces hypertrophy and fibronectin transcription in vascular smooth muscle cells via p38 MAPK and cAMP response element-binding protein activation. Mediation of angiotensin II effects. J. Biol. Chem. 2002, 277:9920-9928.
60. Sagara M., Satoh J., Wada R., Yagihashi S., Takahashi K., Fukuzawa M., Muto G., Muto Y., Toyota T. Inhibition of development of peripheral neuropathy in streptozotocin-induced diabetic rats with N-acetylcysteine. Diabetologia 1996, 39:263-269.
61. Schmeichel A.M., Schmelzer J.D., Low P.A. Oxidative injury and apoptosis of dorsal root ganglion neurons in chronic experimental diabetic neuropathy. Diabetes 2003, 52:165-171.
62. Schroeter H., Boyd C., Spencer J.P., Williams R.J., Cadenas E., Rice-Evans C. MAPK signaling in neurodegeneration: influences of flavonoids and of nitric oxide. Neurobiol. Aging 2002, 23:861-880.
63. Sies H. Polyphenols and health: update and perspectives. Arch. Biochem. Biophys. 2010, 501:2-5.
64. Sima A.A., Kamiya H. Is C-peptide replacement the missing link for successful treatment of neurological complications in type 1 diabetes?. Curr. Drug Targets 2008, 2008(9):37-46.
65. Stavniichuk R., Drel V.R., Shevalye H., Vareniuk I., Stevens M.J., Nadler J.L., Obrosova I.G. Role of 12/15-lipoxygenase in nitrosative stress and peripheral prediabetic and diabetic neuropathies. Free Radic. Biol. Med. 2010, 49:1036-1045.
66. Stevens M.J., Lattimer S.A., Kamijo M., Van Huysen C., Sima A.A., Greene D.A. Osmotically-induced nerve taurine depletion and the compatible osmolyte hypothesis in experimental diabetic neuropathy in the rat. Diabetologia 1993, 36:608-614.
67. Stevens M.J., Obrosova I., Cao X., Van Huysen C., Greene D.A. Effects of dl-alpha-lipoic acid on peripheral nerve conduction, blood flow, energy metabolism, and oxidative stress in experimental diabetic neuropathy. Diabetes 2000, 49:1006-1015.
68. Stevens M.J., Zhang W., Li F., Sima A.A. C-peptide corrects endoneurial blood flow but not oxidative stress in type 1 BB/Wor rats. Am. J. Physiol. Endocrinol. Metab. 2004, 287:E497-E505.
69. Sumner C.J., Sheth S., Griffin J.W., Cornblath D.R., Polydefkis M. The spectrum of neuropathy in diabetes and impaired glucose tolerance. Neurology 2003, 60:108-111.
70. Sun H., Che Q.M., Zhao X., Pu X.P. Antifibrotic effects of chronic baicalein administration in a CCl4 liver fibrosis model in rats. Eur. J. Pharmacol. 2010, 631:53-60.
71. Szabó C., Zanchi A., Komjáti K., Pacher P., Krolewski A.S., Quist W.C., LoGerfo F.W., Horton E.S., Veves A. Poly(ADP-ribose) polymerase is activated in subjects at risk of developing type 2 diabetes and is associated with impaired vascular reactivity. Circulation 2002, 106:2680-2686.
72. Tesfaye S., Boulton A.J., Dyck P.J., Freeman R., Horowitz M., Kempler P., Lauria G., Malik R.A., Spallone V., Vinik A., Bernardi L., Valensi P. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 2010, 33:2285-2293. Toronto Diabetic Neuropathy Expert Group.
73. Toth C., Brussee V., Zochodne D.W. Remote neurotrophic support of epidermal nerve fibres in experimental diabetes. Diabetologia 2006, 49:1081-1088.
74. Toth C., Rong L.L., Yang C., Martinez J., Song F., Ramji N., Brussee V., Liu W., Durand J., Nguyen M.D., Schmidt A.M., Zochodne D.W. Receptor for advanced glycation end products (RAGEs) and experimental diabetic neuropathy. Diabetes 2008, 57:1002-1017.
75. Urban M.J., Li C., Yu C., Lu Y., Krise J.M., McIntosh M.P., Rajewski R.A., Blagg B.S., Dobrowsky R.T. Inhibiting heat-shock protein 90 reverses sensory hypoalgesia in diabetic mice. ASN Neuro 2010, 11. (pii: e00040).
76. Wada R., Nishizawa Y., Yagihashi N., Takeuchi M., Ishikawa Y., Yasumura K., Nakano M., Yagihashi S. Effects of OPB-9195, anti-glycation agent, on experimental diabetic neuropathy. Eur. J. Clin. Invest. 2001, 31:513-520.
77. Wang Y., Schmeichel A.M., Iida H., Schmelzer J.D., Low P.A. Enhanced inflammatory response via activation of NF-kappaB in acute experimental diabetic neuropathy subjected to ischemia-reperfusion injury. J. Neurol. Sci. 2006, 247:47-52.
78. Wang Y., Kawamura N., Schmelzer J.D., Schmeichel A.M., Low P.A. Decreased peripheral nerve damage after ischemia-reperfusion injury in mice lacking TNF-alpha. J. Neurol. Sci. 2008, 267:107-111.
79. Wu Z., Mata M., Fink D.J. Prevention of diabetic neuropathy by regulatable expression of HSV-mediated erythropoietin. Mol. Ther. 2011, 19:310-317.
80. Yagihashi S., Yamagishi S.I., Wada Ri.R., Baba M., Hohman T.C., Yabe-Nishimura C., Kokai Y. Neuropathy in diabetic mice overexpressing human aldose reductase and effects of aldose reductase inhibitor. Brain 2001, 124:2448-2458.
81. Yang L.P., Sun H.L., Wu L.M., Guo X.J., Dou H.L., Tso M.O., Zhao L., Li S.M. Baicalein reduces inflammatory process in a rodent model of diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 2009, 50:2319-2327.
82. Yoo S., Han S., Park Y.S., Lee J.H., Oh U., Hwang S.W. Lipoxygenase inhibitors suppressed carrageenan-induced Fos-expression and inflammatory pain responses in the rat. Mol. Cells 2009, 27:417-422.
83. Yun M.Y., Yang J.H., Kim D.K., Cheong K.J., Song H.H., Kim D.H., Cheong K.J., Kim Y.I., Shin S.C. Therapeutic effects of Baicalein on atopic dermatitis-like skin lesions of NC/Nga mice induced by Dermatophagoides pteronyssinus. Int. Immunopharmacol. 2010, 10:1142-1148.
84. Zhou Y.P., Zhang J.Q. Oral baicalin and liquid extract of licorice reduce sorbitol levels in red blood cell of diabetic rats. Chin. Med. J. (Engl.) 1989, 102:203-206.